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Smallpox Vaccination
Vaccination Method & Reactions
Because routine smallpox vaccination ceased 
30 years ago, many clinicians are unacquainted
with the vaccinia (smallpox) vaccine.
This pocket guide provides health care personnel
with concise information on the vaccine, method
of vaccination and the nature of the expected
responses to vaccination. Additional in-depth
information is available by visiting:
www.bt.cdc.gov/agent/smallpox
The guide also includes images and text to help 
differentiate the more common, self-limiting 
adverse reactions of vaccination from those that 
are serious and may require intervention.
About the Vaccine
The vaccinia (smallpox) vaccine is a live virus that 
multiplies in the superficial layers of the skin. It does not
contain variola virus, the virus that causes smallpox. A
successful vaccination is often referred to as a “take.”
Two vaccine types will be used in the coming years:
1. Calf-lymph vaccine: Dryvax (Wyeth and Aventis)






(1) May protect against a fatal outcome, but not against developing a milder 
form of smallpox
Contraindications for Vaccinees & Their Close 
Physical Contacts (E.g., Household Members)
• Pregnancy
• Immunodeficiencies 
• Extensive skin diseases (1)
• Immunosuppressive therapies (2)
• Inflammatory eye diseases (3)
• Atopic dermatitis (eczema); present, past, or “healed”
• Vaccine component allergy (4)
• Breastfeeding (5)
• Less than 12 months of age (5)
(1) E.g., acne, burns, wounds, recent incisions, impetigo, contact dermatitis
(2) E.g., cancer therapy, organ transplants, other conditions with therapy
(3) Only in vaccinee with eye disease or on steroid eye therapy
(4) Vaccinee (only) allergy to Dryvax component: polymyxin B sulfate, streptomycin 
sulfate, chlortetracycline hydrochloride, neomycin sulfate
(5) Only in vaccinee
Smallpox Outbreak
In the event of a smallpox outbreak, those who normally 
would have a contraindication for vaccination, but who 
are at risk of exposure to smallpox, would be offered 
the vaccination.
Recommended Vaccination Method
Multiple puncture vaccination on the deltoid area of the 
upper arm, using an individually wrapped, sterile, 
bifurcated needle.
Step-by-Step Instructions
1. NO alcohol: vaccination will be inhibited. No skin   
1. preparation is required prior to vaccination.   
2. Dip needle in vaccine vial; a minute drop is retained.
3. Make 3 or 15 (see package insert) perpendicular 
insertions within a 5-mm diameter area. 
NOTE: Strokes should be vigorous enough to evoke a 
trace of blood after 15-30 seconds.
4. Absorb excess vaccine with sterile gauze and discard 
gauze in a biohazard waste receptacle.
5. Cover site with sterile gauze (loosely taped).
6. Prevent contact transmission.
Unlike other immunizations, smallpox vaccination is 
characterized by a virus that propagates in the skin 
and can potentially contaminate the vaccinee's hands 
or the skin and mucosa of others with whom the 
vaccinee comes into contact.
Caution vaccinee and/or guardian (until scab has 
fallen off on its own) to:
•  Keep the vaccination site covered
•  Do not touch, scratch or rub the site, even though 
• it is itchy
•  Avoid person-to-person contact with susceptible 
• individuals (see contraindications)
•  Avoid touching, rubbing or any other maneuvers  
• that might transfer vaccinia virus to the eye or 
• surrounding skin
•  Discard used gauze safely in a sealed plastic bag
•  After handling used gauze, thoroughly wash hands    
Health care worker caution: Treat contaminated materials
as infectious waste.  At work, cover gauze bandage with 






5-6 Vesicle with surrounding erythema -> 
vesicle with depressed center
8-9 Well-formed pustule
12+ Pustule crusts over -> scab
17-21 Scab detaches revealing scar
No Reaction
A non-reaction means no immunity and vaccination
must be repeated.
Systemic Symptoms




• Soreness at the vaccination site
• Local lymphadenopathy
• Intense erythema ringing the vaccination
Normal Variants
Normal variants (rate: 2.4% - 6.6%) are NOT adverse
events and require no specific treatment. 
They include:
• Satellite lesions
• Lymphangitis from the site to regional nodes
• Regional lymphadenopathy
• Considerable local edema at the site




Typical primary reaction   
Major reaction 
Equivocal reaction           
If a patient has never had a successful take, the patient 
should be informed that he/she is almost certainly NOT 
immune.
Vaccinia Immune Globulin (VIG) was produced in the 
1960's from plasma obtained from recently vaccinated 
donors and was administered intramuscularly (IM-VIG).
Recently, intravenous VIG (IV-VIG) has also been 
produced.
Vials of IM-VIG and IV-VIG are stored at the CDC and






The usual dose of IM-VIG is 0.6 ml/kg body weight. 
As much as 1-10 ml/kg body weight has been used in 
serious, life-threatening complications.
To calculate the weight-based dose of IV-VIG, refer to
the IND protocol or package insert that accompanies
the IV-VIG product.  Repeated doses may be necessary
to fully treat adverse events such as eczema 
vaccinatum or progressive vaccinia that present with
more severe clinical manifestations.




(if severe or recurrent)
• Progressive vaccinia
• Accidental implantation 
(mild instances)
• Generalized vaccinia
(mild or limited - most instances)
• Erythema multiforme
• Vaccinia keratitis
(see back of guide for details)
• Post-vaccinial encephalitis
Description
Clear-cut pustule 6-8 days after
vaccination
Area of definite induration or 
congestion surrounding a central 
lesion that may be a scab or 
ulcer 6-8 days after vaccination.
The evolution of the lesion is 
more rapid than following a 
primary reaction.
Any other reaction or response; 
E.g., an "allergic" reaction 
(revaccination is indicated) or 
no reaction (revaccination is
indicated)
Fades after 5 years, after 20
years probably negligible
Found to persist 30+ years (1)
Within 2-3 days, can protect 
against smallpox
Within 4-5 days, may protect 
against a fatal outcome
Discard Properly    Sterile Cover         
Post-insertion        Absorb Excess       
Proper Position      3 or 15 Insertions  
Dip Needle            Retained Vaccine    
Day 6                  Day 8                  Day 10                Day 14                
Day 6                  Day 8                  Day 10                Day 14                
Day 8                  
Most vaccinees experience only a mild fever and local 
discomfort with localized redness and swelling.
Satellite Lesions   Lymphangitis   Edema    
Bifurcated Needle
ADVERSE REACTIONS Adverse Reactions: Accidental Implantation Adverse Reactions: Bacterial Infections Adverse Reactions: Eczema Vaccinatum Adverse Reactions: Erythema Multiforme Adverse Reactions: Generalized Vaccinia Adverse Reactions: Progressive Vaccinia Adverse Reactions: Vaccinia Keratitis
Smallpox (vaccinia) vaccination is a generally
safe, effective preventative against smallpox.
Some individuals may experience an adverse event; 
many are harmless, a few are mild to moderate and
require specific treatment, and rarely, more serious
adverse events occur in susceptible individuals.
Reporting Adverse Events
To report adverse events or request consultation about
an adverse event, please call your state or local public
health authorities.
Accidental Administration
Occasionally, an individual may ingest vaccine accidentally
or may be injected inadvertently by the intramuscular or
subcutaneous route. These are not recommended routes
of administration. It is prudent to follow the individual
clinically and to examine the administration site for a 
vaccination lesion. Severity: Benign   Frequency: Rare
Post-Vaccinial Encephalitis
Post-vaccinial encephalitis is a rare complication of 
primary vaccination (15/million). Encephalitis occurs 
10-14 days after vaccination with headache, vomiting,
drowsiness and fever as the first symptoms. In severe
cases life-threatening complications can develop.
Severity: Severe - hospitalize   Frequency: Rare
Accidental Implantation
Accidental implantation by autoinoculation or contact 
is one of the most common adverse events. Although
no age group is spared, infants and children are most 
susceptible to more extensive inoculations because of
their tendency to scratch an itching vaccination site. 
This surface virus is easily transferred to the hands 
and to fomites. Either may be the source of inoculation
elsewhere, but most implantations occur as a result of
transfer from hand to skin or to mucosa. 
Lesions follow the same course as the primary vaccina-
tion, except in patients with cell-mediated immune 
dysfunction where each lesion progresses without an
inflammatory response, does not heal, and expands.
If there are only one or a few lesions, no specific treat-
ment is required. Multiple lesions, especially if they are
confluent and cover large portions of the body warrant
treatment with Vaccinia Immune Globulin (VIG).
Severity: Mild to severe - hospitalize severe
Frequency: Common
VIG: Indicated with extensive lesions
VIG: Not recommended for mild instances
Bacterial Infections
Bacterial infections of the vaccination site are not 
common. Children are at greater risk as they may
manipulate the site more often and contaminate the
vaccination. Occlusive dressings may lead to maceration
and increased risk of infection. 
The most common organisms are Staphylococcus aureus
and Group A Beta Hemolytic Streptococci. Anaerobic
organisms occasionally infect the site. Impetiginous 
vesiculo-pustular lesions are seen in staph infection and
piled-up eschar formation is common in streptococcal
infections, although lesions identical to the staph infec-
tions also occur. Mixed infections may be encountered.
Bacterial cultures should be obtained from the site by
swabbing or aspiration.
Treatment is with antibiotics specific to the agent. Initial






Individuals with eczema (i.e., atopic dermatitis), active 
or healed, are at special risk from implantation of 
vaccinia virus into the diseased skin, sometimes with 
a fatal outcome. 
Transfer of vaccinia virus can occur from autoinoculation
or from contact with a vaccinee whose lesion is in the
florid stages. Because most individuals have large con-
tiguous patches of skin in the affected areas, confluent
lesions are the rule (on the face and limbs primarily). 
Diagnosis may be more difficult in contact cases, because
history of contact with a vaccinee may be unknown or
unappreciated as to risk.
With early recognition and prompt treatment with Vaccinia
Immune Globulin (VIG), mortality can be reduced to zero,
and morbidity alleviated. Scarring may be extensive.




Toxic and/or hypersensitivity rashes are common 1-2
weeks after vaccination. The rash varies from erythema-
tous macular lesions, to vesicles, urticaria, pustules and
typical bulls-eye lesions, all under the rubric “erythema
multiforme”. These are benign lesions that do not pro-
gress. Itching may accompany the rash. The most serious
reaction, Stevens-Johnson Syndrome (SJS) is rare.
Diagnosis is by typical rash seen in temporal association
with primary vaccination. In the vesicular and pustular
forms it is necessary to distinguish these from general-
ized vaccinia or inoculation vaccinia. The vesicles and
pustules in erythema multiforme do not progress into
typical vaccinations and usually can be distinguished on
this basis.
Treatment is symptomatic, usually employing an anti-
histamine and measures to counteract itching, if present.
Mucosal involvement and evolution into SJS requires
hospitalization and supportive care.
Severity: Benign
(exception: Stevens-Johnson Syndrome (SJS) - severe)
Frequency: Most common (exception: SJS - rare)
VIG: Not recommended
Generalized Vaccinia 
Generalized vaccinia is rare, usually benign, and the
result of viremia. Within a week, lesions appear on any
part of the body (most often on the trunk and abdomen,
less commonly on the face, limbs, palms and soles).
Lesions undergo rapid evolution to scarring. Rarely,
lesions may recur at 4-6 week intervals for as long as
one year.
Subtle minor immunologic abnormalities, particularly 
of the immunoglobulin B-cell system, are suspected to
be present. Differentiate from erythema multiforme,
eczema vaccinatum, progressive vaccinia, severe chicken-
pox and smallpox. Consultation with an immunologist is
strongly recommended.
Most instances of generalized vaccinia, particularly if 
the lesions are few, require no specific therapy. In some
cases, with extensive lesions, or in recurrent disease,
Vaccinia Immune Globulin (VIG) should be administered.
Severity: Benign, avoid hospitalization 
(exception: recurrent generalized vaccinia - hospitalize)
Frequency: Rare
(exception: recurrent generalized vaccinia - very rare)
VIG: Indicated (if severe or recurrent) 
Not recommended (if mild or limited - most instances) 
Progressive Vaccinia 
Progressive vaccinia is a rare complication occurring 
primarily in T-cell deficient persons. Congenital T-cell
deficient children, those with T-cell deficient diseases
(cancer, immunosuppressive therapy, HIV/AIDS) are 
at risk.
The primary vaccination fails to heal and spreads locally
and by viremia to other parts of the body; each lesion
spreads without inflammatory response. Untreated
patients succumb to viral effect or to secondary fungal,
parasitic or bacterial infections.
Complications include septic shock, disseminated
intravascular coagulation, and superimposed microbial 
infections. If viable lymphocytes are administered, the
patient may experience graft-versus-host disease.
Viral and immunologic laboratory investigation is
mandatory. Therapy consists of intensive administration
of antibody, usually in the form of Vaccinia Immune
Globulin (VIG).




Although rare, vaccinia virus can be implanted into the 
periorbital structures and even into the cornea.  Viral
replication and the immune response lead to ulceration
with subsequent corneal scarring or clouding.
Ten days after inoculation the clinical signs appear; 
a central, grayish, disciform corneal lesion is most 
common.  Topical antiviral agents are the treatment 
of choice in consultation with an experienced 
ophthalmologist.
Vaccinia Immune Globulin (VIG) is not recommended
for vaccinia keratitis, but should be given if it occurs as
part of a life-threatening complication, such as eczema
vaccinatum or progressive vaccinia, in which case it
must be administered.  In instances of severe 
periorbital disease accompanied by keratitis, VIG is not
recommended, but some experts believe that it can be
administered in a single dose at 0.6 ml/kg, or at most
two such doses.
Severity: Severe if untreated
Frequency: Rare
VIG: Not recommended as noted above, consult with  
CDC for up-to-date information
